What is the typical dose of FOXO4-DRI?

Typical research doses are 5-10 mg, administered 3x weekly. Commonly timed: Any time of day. These are research figures only — not clinical recommendations.

What are the known side effects of FOXO4-DRI?

Side effects reported in research include: Local injection site reactions (common, mild); Injection site discomfort or pain (common, mild); Lipodystrophy (localized fat loss or thickening) (uncommon, moderate); Systemic inflammatory response (rare, moderate); Allergic reaction (rare, serious); Infection at injection site (rare, serious). Always consult a qualified professional before use.

How is FOXO4-DRI administered?

FOXO4-DRI is typically administered via Topical.

What is the evidence quality for FOXO4-DRI?

FOXO4-DRI carries an evidence grade of D. Grade D — theoretical or very preliminary evidence only.

Skin & Anti-Aging / Topical

FOXO4-DRI

Q: What is FOXO4-DRI used for in research?

Research on FOXO4-DRI has focused on: Selectively eliminates senescent cells; May improve skin elasticity and texture; Supports tissue regeneration and repair; Potential anti-inflammatory effects; May enhance dermal collagen production.

A senolytic peptide that selectively targets and eliminates senescent (zombie) cells by disrupting the FOXO4-p53 interaction. Being researched for anti-aging and tissue rejuvenation applications.

What is FOXO4-DRI used for? Research has focused on selectively eliminates senescent cells; may improve skin elasticity and texture; supports tissue regeneration and repair.

Compare with other peptides studied forrecovery and healing,skin health,longevity and anti-aging

Evidence grade DResearch only

Beginner basics

Plain-English guide to FOXO4-DRI

What it does: This peptide targets and removes 'zombie cells'-old, damaged cells that accumulate in skin and tissues over time. Researchers study it for potentially improving skin firmness and supporting the body's natural repair processes.
Typical dose: Researchers commonly use 5-10 mg applied topically three times per week, often applied as a cream or lotion with 0.1-1% concentration. Dosing varies widely in research, so start with a lower amount and adjust based on how your skin responds.
When to inject: Topical application can be done any time of day. Many researchers cycle it (8 weeks on, 4 weeks off) to monitor effects and prevent the body from adapting to it.
Storage: Keep the dry powder in a freezer at -20°C before mixing. Once you mix it with liquid, store it in a regular refrigerator (2-8°C). Keep it away from direct light.
Beginner tip: Start with the lowest recommended amount and use it consistently for at least 4-8 weeks before deciding if it's working, since skin changes take time to become visible.

Research status

Evidence grade D: Theoretical or in-vitro only, with no meaningful independent human evidence.
Research only: No regulatory approval in any major jurisdiction. Research use only.

Early Research

For research purposes only. Not approved for human use. Not medical advice.

Research areas

Selectively eliminates senescent cells
May improve skin elasticity and texture
Supports tissue regeneration and repair
Potential anti-inflammatory effects
May enhance dermal collagen production

Side effects

Effect	How often	Severity
Local injection site reactionsRedness, mild swelling, or bruising at the injection site. Usually resolves within 24-48 hours. Minimize by rotating sites, allowing solution to reach room temperature, and using proper injection technique.	Common	Mild
Injection site discomfort or painMild stinging or soreness during or immediately after injection. Typically resolves within minutes. Reduced by allowing the peptide solution to warm to room temperature before injection.	Common	Mild
Lipodystrophy (localized fat loss or thickening)Repeated injections at the same site can cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Prevent by strictly rotating injection sites with each dose and maintaining at least 1 inch between injection points.	Uncommon	Moderate
Systemic inflammatory responseTransient fever, malaise, or mild systemic inflammation may occur as senescent cells are cleared and release inflammatory mediators. This is theoretically possible but not well-documented in human studies. Monitor and contact a healthcare provider if symptoms are severe.	Rare	Moderate
Allergic reactionAnaphylaxis or severe allergic reaction is rare but possible with any peptide. Signs include difficulty breathing, facial swelling, severe itching, or rapid heartbeat. Seek emergency medical attention immediately if these occur.	Rare	Serious
Infection at injection siteBacterial infection can occur if sterile technique is not followed. Signs include increasing redness, warmth, pus, or fever. Seek medical attention if infection is suspected.	Rare	Serious

Dosing reference

Dose scale from the research

Starting: 5 mg
Upper end: 10 mg

FOXO4-DRI dosing reference
Parameter	Value
Dose range	5-10 mg
Frequency, timing and route are for members Sign up free Log in

Checked October 2026

Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration

Work out your exact dose in the free peptide calculator

Storage and stability

Store lyophilized peptide at -20°C. Refrigerate after reconstitution (2-8°C). Protect from light.

Molecular and pharmacological data

FOXO4-DRI is a senolytic peptide that disrupts the interaction between the FOXO4 protein and p53 in senescent cells, leading to their selective apoptosis (programmed cell death). Senescent cells accumulate with age and contribute to tissue dysfunction and inflammation. By eliminating these 'zombie' cells, FOXO4-DRI aims to restore tissue homeostasis and support regeneration.

Pathways and mechanism detail are for members

Keep a log of your FOXO4-DRI research

Free account. No credit card required.

Start free Goal finder Interaction checker

Recent research

All results on PubMed

Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.

Research citations

4 sources

Baar et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Nature Cell Biology, 19(12), 1319-1330. PMID: 29106404
Xu et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature Medicine, 24(8), 1246-1256. PMID: 30050112
Kirkland & Tchkonia (2017). Cellular senescence: A translational perspective. EBioMedicine, 21, 21-28. PMID: 28396075
Zhu et al. (2015). The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell, 14(4), 644-658. PMID: 25754370

All Skin & Anti-Aging peptides

Browse the research library

147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.

View all peptides

Stay updated on FOXO4-DRI research

A weekly digest of new peptide research, stack guides and site updates.

Research use only. All content on this page is provided for informational and educational purposes related to scientific research. FOXO4-DRI is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.